Aidan King
Founder chez Fountain Healthcare Partners Ltd.
Profil
Aidan King is Managing Partner and co-founder of Fountain Healthcare Partners.
Aidan qualified as a pharmacist from Trinity College Dublin and in 1992 joined Elan Corporation’s strategic marketing group with the responsibility of identifying and evaluating product development candidates for Elan’s drug delivery technologies.
In 1996, Aidan assumed Head of Strategic Marketing for Elan’s drug delivery division with a focus on competitive analysis and strategic positioning of Elan’s technology platforms.
Having completed an MBA at University College Dublin in 1998, Aidan moved to the U.S.
as one of the founding members of Elan’s corporate venture capital group.
Over the next five years, Aidan undertook over twenty strategic investments in public and private specialty pharma, biotechnology and medical device companies, in the U.S., Canada and Europe.
Investments included Quadrant Healthcare (acquired by Elan, 2000), Atrix laboratories (acquired by QLT, 2004), Idun Pharmaceuticals (acquired by Pfizer, 2005) and Zealand Pharmaceuticals (IPO, 2010).
In 2004, Aidan joined Bio-IB, a New York based boutique life science investment bank where he was responsible for M&A and strategic licensing transactions.
Aidan is a CFA charter holder.
He currently sits on the boards of Xylocor Therapeutics, Corteria Pharmaceuticals and Ermium Therapeutics.
Previously, he was the firm’s representative on the boards of Syndesi Therapeutics (acquired by Abbvie, 2022), Civitas Therapeutics (acquired by Acorda, 2014), Chrono Therapeutics, Velicept Therapeutics and Palyon Medical.
Postes actifs de Aidan King
| Sociétés | Poste | Début |
|---|---|---|
Fountain Healthcare Partners Ltd.
 Fountain Healthcare Partners Ltd. Investment ManagersFinance Fountain Healthcare Partners Ltd. (Fountain) is venture capital firm, founded in 2008 by Manus Rogan and Aidan King. The firm is headquartered in Dublin, Ireland. | Founder | 01/01/2008 |
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Director/Board Member | 01/01/2021 |
Ermium Therapeutics SAS
 Ermium Therapeutics SAS BiotechnologyHealth Technology Ermium Therapeutics SAS is a biotechnology company, which develops therapies for auto-immune diseases. It specializes in conditions such as systemic lupus erythematous, multiple sclerosis, and rheumatoid arthritis. The company was founded by Joël Crouzet and Jean-Philippe Herbeuval in June 2019 and is headquartered in Paris, France. | Director/Board Member | 01/06/2022 |
Corteria Pharmaceuticals
 Corteria Pharmaceuticals Pharmaceuticals: MajorHealth Technology Corteria Pharmaceuticals is a privately held French company founded in 2021 that focuses on developing transformative therapies for the treatment of worsening and acute decompensated heart failure, sarcopenia, and obesity subpopulations. The company is based in Paris, France. The company's strategy involves innovative patient stratification and target identification. Corticotropin-releasing hormone receptor 2 (CRF2) is a plasma membrane receptor widely expressed in the cardiovascular, renal, and metabolic systems, and in proof of concept studies in heart failure patients and preclinical heart failure models, CRF2 agonists have been shown to improve cardiac function and reduce pulmonary congestion. The CEO is Philip Janiak. | Director/Board Member | 01/03/2022 |
Anciens postes connus de Aidan King
| Sociétés | Poste | Fin |
|---|---|---|
Syndesi Therapeutics SA
 Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Director/Board Member | 01/02/2022 |
Velicept Therapeutics, Inc.
 Velicept Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Velicept Therapeutics, Inc. manufactures biopharmaceutical products. The firm offers Solabegron, which is used for the treatment of overactive bladder in women and irritable bowel syndrome. The company was founded in 2015 and is headquartered in Wayne, PA. | Director/Board Member | 01/12/2020 |
Chrono Therapeutics, Inc.
 Chrono Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Chrono Therapeutics, Inc. produces transdermal drug products. It is a pharmaceutical company with a vision of transforming disease and addiction management to become the market leader in programmable passive transdermal drug delivery that offers real-time behavioral support. The company was founded by Guy DiPierro in 2004 and is headquartered in Hayward, CA. | Director/Board Member | 01/10/2019 |
Civitas Therapeutics, Inc.
 Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Director/Board Member | 01/10/2015 |
Palyon Medical Corp.
 Palyon Medical Corp. Medical SpecialtiesHealth Technology Palyon Medical Corp. develops medical devices for the treatment of chronic pain, spasticity and other neurological diseases. The company was founded by Greg David, David A. Present and Klaus G. Lederer on May 16, 2003 and is headquartered in Santa Clarita, CA. | Director/Board Member | 01/07/2015 |
Formation de Aidan King
| University College Dublin | Masters Business Admin |
| Trinity College Dublin | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Elan Corp. Plc
 Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Health Technology |
Chrono Therapeutics, Inc.
Chrono Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Chrono Therapeutics, Inc. produces transdermal drug products. It is a pharmaceutical company with a vision of transforming disease and addiction management to become the market leader in programmable passive transdermal drug delivery that offers real-time behavioral support. The company was founded by Guy DiPierro in 2004 and is headquartered in Hayward, CA. | Commercial Services |
Fountain Healthcare Partners Ltd.
Fountain Healthcare Partners Ltd. Investment ManagersFinance Fountain Healthcare Partners Ltd. (Fountain) is venture capital firm, founded in 2008 by Manus Rogan and Aidan King. The firm is headquartered in Dublin, Ireland. | Finance |
Palyon Medical Corp.
Palyon Medical Corp. Medical SpecialtiesHealth Technology Palyon Medical Corp. develops medical devices for the treatment of chronic pain, spasticity and other neurological diseases. The company was founded by Greg David, David A. Present and Klaus G. Lederer on May 16, 2003 and is headquartered in Santa Clarita, CA. | Health Technology |
Civitas Therapeutics, Inc.
Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Health Technology |
Velicept Therapeutics, Inc.
Velicept Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Velicept Therapeutics, Inc. manufactures biopharmaceutical products. The firm offers Solabegron, which is used for the treatment of overactive bladder in women and irritable bowel syndrome. The company was founded in 2015 and is headquartered in Wayne, PA. | Health Technology |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Health Technology |
Syndesi Therapeutics SA
Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Commercial Services |
Ermium Therapeutics SAS
Ermium Therapeutics SAS BiotechnologyHealth Technology Ermium Therapeutics SAS is a biotechnology company, which develops therapies for auto-immune diseases. It specializes in conditions such as systemic lupus erythematous, multiple sclerosis, and rheumatoid arthritis. The company was founded by Joël Crouzet and Jean-Philippe Herbeuval in June 2019 and is headquartered in Paris, France. | Health Technology |
Corteria Pharmaceuticals
Corteria Pharmaceuticals Pharmaceuticals: MajorHealth Technology Corteria Pharmaceuticals is a privately held French company founded in 2021 that focuses on developing transformative therapies for the treatment of worsening and acute decompensated heart failure, sarcopenia, and obesity subpopulations. The company is based in Paris, France. The company's strategy involves innovative patient stratification and target identification. Corticotropin-releasing hormone receptor 2 (CRF2) is a plasma membrane receptor widely expressed in the cardiovascular, renal, and metabolic systems, and in proof of concept studies in heart failure patients and preclinical heart failure models, CRF2 agonists have been shown to improve cardiac function and reduce pulmonary congestion. The CEO is Philip Janiak. | Health Technology |
